Infectious pulmonary complications in patients treated with anti-TNF-α monoclonal antibodies and soluble TNF receptor

Current Infectious Disease Reports

Volumn 11, Issue 3, 2009, Pages 229-236

  Carbone, Javier ^a   Perez Rojas, Javier ^a   Sarmiento, Elizabeth ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; FLUCONAZOLE; GAMMA INTERFERON; INFLIXIMAB; ISONIAZID; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACTINOMYCOSIS; ANKYLOSING SPONDYLITIS; ASPERGILLOSIS; ATYPICAL MYCOBACTERIOSIS; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CELLULITIS; CHICKENPOX; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; DISEASE PREDISPOSITION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HIGH RISK POPULATION; HISTOPLASMOSIS; HUMAN; IMMUNE FUNCTION TEST; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTIOUS PNEUMONIA; INVASIVE CANDIDIASIS; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY INFECTION; LOWER RESPIRATORY TRACT INFECTION; LUNG ASPERGILLOSIS; LUNG INFECTION; MEDLINE; MYCOBACTERIOSIS; MYCOSIS; NECROTIZING FASCIITIS; NONHUMAN; PATIENT COMPLIANCE; PATIENT MONITORING; PNEUMOCOCCAL INFECTION; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; POSTMARKETING SURVEILLANCE; PREDICTION; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SINGLE DRUG DOSE; SOFT TISSUE INFECTION; THORAX RADIOGRAPHY; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS; ULCERATIVE COLITIS; URINARY TRACT INFECTION; VIRAL RESPIRATORY TRACT INFECTION; VIRUS PNEUMONIA;

EID: 65649105105     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-009-0034-2     Document Type: Review

References (50)

1. Lin J, Ziring D, Desai S, eA al.: TNFa blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008, 126:13-30.
2. Furst DE: The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2008 (Epub ahead of print).
3. Yamamura M: Monitoring of clinical course in TNF inhibitor treatment for rheumatoid arthritis - efficacy evaluation, adverse effect detection, and prediction of clinical response. Nippon Rinsho 2007, 65:1269-1275.
4. Saliu OY, Sofer C, Stein DS, et al.: Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006, 194:486-492.
5. Harris J, Hope JC, Keane J: Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis. J Infect Dis 2008, 198:1842-1850.
6. Plessner HL, Lin PL, Kohno T, et al.: Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 2007, 195:1643-1650.
7. Wolfe F, Michaud K, Anderson J, Urbansky K: Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004, 50:372-379.
8. Mohan VP, Scanga CA, Yu K, et al.: Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001, 69:1847-1855.
9. Schiff MH, Burmester GR, Kent JD, et al.: Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:889-894.
10. Gómez-Reino JJ, Carmona L, Angel Descalzo M; Biobadaser Group: Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007, 57:756-761.
11. Winthrop KL: Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006, 2:602-610.
12. Doherty SD, Van Voorhees A, Lebwohl MG, et al.: National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 2008, 59:209-217.
13. British Thoracic Society Standards of Care Committee: BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005, 6:800-805.
14. Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004, 53:683-686.
15. Fuchs I, Avnon L, Freud T, Abu-Shakra M: Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors. Clin Rheumatol 2009, 28:167-172.
16. López-San Román A, Obrador A, Fortún J, et al.: Recommendations on tuberculosis and treatment of inflammatory bowel disease with infliximab. 2006 Update. Gastroenterol Hepatol 2006, 29:81-84.
17. Saag KG, Teng GG, Patkar NM, et al.: American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59:762-784.
18. Sellam J, Hamdi H, Roy C, et al.: Comparison of in vitrospecific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 2007, 66:1610-1615.
19. Mazurek GH, Jereb J, Lobue P, et al.: Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005, 54:49-55.
20. Matulis G, Jüni P, Villiger PM, Gadola SD: Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases performance of a mycobacterium tuberculosis antigen specific IFN-gamma assay. Ann Rheum Dis 2008, 67:84-90.
21. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, et al.: Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008, 35:776-81.
22. Bourikas LA, Kourbeti IS, Koutsopoulos AV, Koutroubakis IE: Disseminated tuberculosis in a Crohn's disease patient on anti-TNF alpha therapy despite chemoprophylaxis. Gut 2005, 54:1360-1362.
23. Salvana EM, Cooper GS, Salata RA: Mycobacterium other than tuberculosis (MOTT) infection: An emerging disease in infliximab-treated patients. J Infect 2007, 55:484-487.
24. Wallis RS, Broder MS, Wong JY, et al.: Granulomatous disease and TNF antagonists. Clin Infect Dis 2004, 38:1261-5.
25. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP: Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008, 83:181-194.
26. Wood KL, Hage CA, Knox KS, et al.: Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med 2003, 167:1279-1282.
27. Koike R, Takeuchi T, Eguchi K, Miyasaka N: Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 2007, 17:451-458.
28. Kaur N, Mahl TC: Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: A review of 84 cases. Inflamm Bowel Dis 2008, 14:721-722.
29. Chiller TM, Galgiani JN, Stevens DA: Coccidioidomycosis. Infect Dis Clin North Am 2003, 17:41-57.
30. Mertz LE, Blair JE: Coccidioidomycosis in rheumatology patients: incidence and potential risk factors. Ann N Y Acad Sci 2007, 1111:343-357.
31. Bergstrom L, Yocum DE, Ampel NM, et al.: Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 2004, 50:1959-1966.
32. St Clair EW, van der Heijde DM, Smolen JS, et al.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheum 2004, 50:3432-3443.
33. van der Heijde D, Kivitz A, Schiff MH, et al.: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, doubleblind, placebo-controlled trial. Arthritis Rheum 2006, 54:2136-2146.
34. Davis JC, van der Heijde DM, Braun J, et al.: Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheumc Dis 2005, 64:1557-1562.
35. Bongartz T, Sutton AJ, Sweeting MJ, et al.: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
36. Curtis JR, Patkar N, Xie A, et al.: Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007, 56:1125-1133.
37. Schneeweiss S, Setoguchi S, Weinblatt ME, et al.: Antitumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007, 56:1754-1764.
38. Wolfe F, Mitchell DM, Sibley JT, et al.: The mortality of rheumatoid arthritis. Arthritis Rheum 1994, 37:481-494.
39. Strangfeld A, Listing J: Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol 2006, 20:1181-1195.
40. Tubach F, Ravaud P, Salmon-Céron D, et al.: Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis 2006, 43:95-100.
41. Domm S, Cinatl J, Mrowietz U: The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: A review of the literature. Br J Dermatol 2008, 159:1217-1228.
42. Helbling D, Breitbach TH, Krause M: Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol 2002, 14:1393-1395.
43. Ito M, Nakano T, Kamiya T, et al.: Effects of tumor necrosis factor alpha on replication of varicella-zoster virus. Antiviral Res 1991, 15:183-192.
44. Leung VS, Nguyen MT, Bush TM: Disseminated primary varicella after initiation of infliximab for Crohn's disease. Am J Gastroenterol 2004, 99:2503-2504.
45. Elkon KB, Liu CC, Gall JG, et al.: Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors. Proc Natl Acad Sci U S A 1997, 94:9814-9819.
46. Ahmad NM, Ahmad KM, Younus F: Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease. J Infect 2007, 54:29-32.
47. Kang MJ, Kim MS, Choi EH, et al.: Adenoviral pneumonia during etanercept treatment in a patient with rheumatoid arthritis. Korean J Intern Med 2007, 22:63-66.
48. Smith CH, Anstey AV, Barker JN, et al.: British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005, 153:486-497.
49. Sarmiento E, Rodriguez-Molina JJ, Fernandez-Yañez J, et al.: IgG monitoring to identify the risk for development of infection in heart transplant recipients. Transpl Infect Dis 2006, 8:49-53.
50. Carbone J, Gonzalez-Lara V, Sarmiento E, et al.: Humoral and cellular monitoring to predict the development of infection in Crohn's disease patients beginning treatment with infliximab. Ann N Y Acad Sci 2007, 1107:346-355.